Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 342

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 342
---
 of Contents

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited) 

(In thousands, except share and per share data)

 Three Months Ended September 30,Nine Months Ended September 30, 2025202420252024Revenue:Product sales, net$133,010 $90,302 $372,380 $236,979 License and other revenue— 75 — 495 Total revenue133,010 90,377 372,380 237,474 Operating expenses:Cost of sales25,537 20,806 71,976 58,863 Research and development42,960 31,710 135,071 96,604 Selling, general and administrative61,910 50,545 182,902 145,391 Total operating expenses130,407 103,061 389,949 300,858 Income (loss) from operations2,603 (12,684)(17,569)(63,384)Other income (expense):Interest income3,251 3,469 9,307 10,588 Interest expense(3,606)(3,586)(10,791)(10,732)Other income (expense), net395 (1,087)2,589 982 Net income (loss) before provision for income taxes2,643 (13,888)(16,464)(62,546)(Benefit from) provision for income taxes(262)347 1,169 1,606 Net income (loss)$2,905 $(14,235)$(17,633)$(64,152)Net income (loss) per share, basic$0.06 $(0.30)$(0.35)$(1.36)Net income (loss) per share, diluted$0.05 $(0.30)$(0.35)$(1.36)Weighted-average shares of common stock outstanding, basic50,639,23147,782,61949,758,10447,316,789Weighted-average shares of common stock outstanding, diluted56,993,84147,782,61949,758,10447,316,789

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

Table of Contents

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(Unaudited)

(In